The ibsa group

THE IBSA GROUP

1. 
   IBSA INSTITUT BIOCHIMIQUE SA
   

IBSA Institut Biochimique SA was founded in 1945 by a group of Swiss biolologists with its head office in Lugano.
IBSA Institut Biochimique represents the headquarters of the IBSA group.
After an initial phase of consolidation at national level, IBSA experienced a period of rapid expansion and even developed an international reputation starting in 1985, the year in which the current chairman took over as head of the company.
Under the new management the company adopted a strategy of optimizing the use of active ingredients for developing innovative pharmaceutical forms capable of improving patient compliance and improving the treatment required.

The activities cover 7 main treatment areas (reproduction and fertility, respiratory, rheumatology, urology, pain/inflammation, dermatology and dermocosmetics, endocrinology), with over 60 exclusive patents.

Currently the IBSA group employs over 1,800 people; IBSA is present in over 70 countries, either from its registered offices in Italy, France, Hungary, Slovak Republic, Poland, Turkey and China, or through international partnerships.
The production facilities are in Switzerland, Italy and the Far East and all are in strict compliance with the highest standards of quality and in line with current regulations. By controlling the steps from production to the delivery of the finished product, IBSA is capable of guaranteeing high quality standards for all products from the various therapeutic areas.

Every year IBSA produces 21 million pre-filled vials, 600 million soft gel capsules, 80 million films for oral use, 320 million transdermal patches.

2. 
   IBSA FARMACEUTICI ITALIA
   

The IBSA Italia offices and production site are in Lodi, near Milan.

The company aim is to increase its reputation and influence in the health world with innovative, competitive and niche products. Creating innovative products means for IBSA Italia the refinement of solutions to respond to the patient’s real needs, which is felt to lie at the heart of scientific research.

With a turnover of over 100 million euro, 350 employees working in two production plants, 8 different pharmaceutical lines, 2 research centres and a factory dedicated to diagnostics, IBSA Italia is one of the top companies in the pharmaceutical sector.
In 2010, the company was further strengthened by the 100% acquisition of Bouty, an Italian leader in distribution to pharmacies and the mass market and for diagnostics. Bouty also stands out due to its advanced production technologies and its ability to respond with the greatest flexibility to the most urgent and unexpected market requirements, thanks to a distribution and delivery system which is always efficient and accurate. So today IBSA Italia is even more competitive, in a pharmaceutical sector where a successful company is able to combine production force with efficient distribution.
IBSA Italia is a European leader in the preparation of pre-filled syringes of hyaluronic acid intended for the orthopaedic and dermocosmetic markets. The formulations based on hyaluronic acid are all innovative and made in highly specialised production plants GMP (Good Manufacturing Practice) approved.
The company also offers contract manufacturing services for the pharmaceutical and nutritional industry, at international level. The production lines are:

- injectable pharmaceutical forms, either aseptic or with terminal sterilisation, topical, suppositories and ovules

- medical devices

- nutritional products in soft gelatin capsules.

3. IBSA HYALURONIC ACID

The molecule used in IBSA products complies with a high standard of quality which allows it to be used in both the pharmaceutical and the dermocosmetic ranges.

This type of hyaluronic acid is produced in a modern biotechnological unit at Altergon Italia using a process requiring several phases, starting with bacterial fermentation and passing through intermediate steps of filtration and purification, to finally obtain a highly purified finished product.

By using a production system which uses biofermentation, the hyaluronic acid produced by IBSA is not contaminated by products derived from animals, eliminating any possible risk of allergy or the transmission of any pathogenic agents (e.g. viruses or prions).

4.PROPERTIES AND PRODUCTION OF IBSA HYALURONIC ACID:

ALTERGON ITALIA

In 2005 IBSA entered into a partnership with Altergon Italia for the production of hyaluronic acid. Based in Morra De Sanctis (Avellino), Altergon Italia was set up in 2000 by Altergon SA, founded in Switzerland with the mission of developing innovative pharmacological formulations and new active ingredients for pharmaceutical use.

As a result of its intense research and development activity, Altergon Italia is currently establishing an innovative plant for the production of hyaluronic acid using a multiphase process which, starting from bacterial fermentation and passing through intermediate stages of filtration and purification, finally obtains a highly purified finished product for pharmaceutical and dermocosmetic use.
The use of this type of hyaluronic acid guarantees the high standard of quality and excellent tolerability of IBSA products.
Moreover, Altergon is a modern plant for the production of medicated plasters.